Yesterday, Aker Biomarine voluntarily withdrew its complaint at the International Trade Commission (ITC), alleging that krill manufacturer Rimfrost had violated several of its patents.
“This is good news, showing that we have been right all along. Aker Biomarine has no case, because you cannot patent nature itself”, says owner Stig Remøy.
Aker Biomarine’s patent dispute with Rimfrost has had negative effects on the global krill market. As the ITC case closes, new market opportunities for Rimfrost are emerging.
“Rimfrost’s ambitions with krill are extensive. Our considerable krill oil capacities allow us to market worldwide. In addition, krill has major potential in the aquaculture market. Our technology increases growth and improves health for farmed salmon”, Remøy says.
Without succeeding, Aker Biomarine has, over time, acted aggressively towards Rimfrost. As Aker Biomarine has now unilaterally withdrawn its ITC complaint, the U.S. Patent Trial and Appeal Board (PTAB) will consider four of Rimfrost’s petitions against Aker Biomarine’s patents.
“We are observing that Aker Biomarine adopts harsh methods in an attempt to usurp a global krill monopoly. This will not succeed, and cannot be accepted by us. When krill licenses were allocated in 2007, Norwegian authorities made it clear that it is in the nation's interest that licenses are distributed to multiple players”, Remøy says.
For further information, please contact:
Owner Stig Remøy
RIMFROST AS
+47 916 19 124
In their second quarter report 2017, Aker ASA misinforms the market about Aker Biomarines ownership in patents and intellectual property rights in connection with the purchase of F/T Juvel.
Norwegian krill manufacturer RIMFROST notes that the global demand for krill oil for human consumption increases, and begins the planning of a new vessel. “After several challenging years, the global krill market is now showing real signs of recovery”, owner of RIMFROST, Stig Remøy, says.
RIMFROST AS is a Norwegian biotechnology company which supplies its RIMFROST Sublime krill oil to the world’s food supplement markets. The company is experiencing increasing sales and market share growth, especially the USA and Europe. The strategy of RIMFROST is now to expand into China and offer a high quality krill oil with superior color and viscosity which meets the regulatory requirements of Chinese authorities. As a first step RIMFROST has been successful in obtaining regulatory approval from the National Health and Family Planning Commission (NHFMC).
Yesterday, Aker Biomarine voluntarily withdrew its complaint at the International Trade Commission (ITC), alleging that krill manufacturer Rimfrost had violated several of its patents.
As the Holiday Season is upon us, the RIMFROST TEAM wants to wish you a very Merry Christmas and a New Year filled with peace and prosperity.
We are attending this years Supply Side West show and hope to see you there. Stop by our booth #PP165 and lets talk krill.
RIMFROST in collaboration with partners in New Zealand has developed and patented a krill powder for human nutraceutical applications. In a long term collaboration with the University in Bergen, with the financial support from the Norwegian Research Council, krill products have been tested in animal models and in humans and the results have been published in international scientific journals. The most recent data shows that krill powder is effective in reducing atherosclerosis in apo E-/- mice, suggesting that it also may be effective in improving vascular health in humans.
RIMFROST AS is a Norwegian vertically integrated krill company which offers krill oil and krill powder to worlds food supplement markets. The company’s strategy to offer this product in South America has now reached a milestone as the company has been granted regulatory approval in Brazil.
RIMFROST AS is a Norwegian vertically integrated biotechnology company that operates and controls the production of high quality krill products from raw material to finished capsules. The company’s recent innovation, a 100% pure krill oil extract with 60% phospholipids, has now obtained a favourable opinion from the Finnish Novel Food Board based on substantial equivalence and is therefore ready for the European market.
In a collaboration with NOFIMA and Denmark Technical University, two stability studies have been performed, showing that the krill powder is stable and minimal degradation takes place.
RIMFROST AS has published a randomized, single-dose, cross-over trial in Lipids in Health and Disease which documents the bioavailability of fatty acids from RIMFROST krill products and fish oil in healthy humans.
Olympic Seafood AS has today received confirmation that its krill fishery is now certified by the Marine Stewardship Council (MSC).
